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Background and Purpose: Endovascular treatment (EVT) for acute vertebrobasilar
intracranial atherosclerosis-related large vessel occlusion (ICAS-LVO) and its outcomes
are not well known. We aimed to evaluate endovascular and clinical outcomes of
vertebrobasilar ICAS-LVO patients who underwent EVT.
Methods: Consecutive acute stroke patients who underwent EVT for vertebrobasilar
LVO were retrospectively reviewed. Patients were assigned to the ICAS (+) or the ICAS
(–) group based on angiographical findings. Procedural details and clinical outcomes
were compared between the ICAS (+) and ICAS (–) groups.
Results: This study included 77 patients with acute vertebrobasilar LVO who underwent
EVT. Among the study subjects, 24 (31.2%) had an ICAS-LVO. Recanalization was
achieved in 19 patients in the ICAS (+) group (79.2%), which was comparable
with the ICAS (–) group (84.9%; p = 0.529). However, recanalization using
conventional endovascular modalities (stent retriever thrombectomy, contact aspiration
thrombectomy, or intra-arterial urokinase infusion) was less successful in the ICAS (+)
group (36.8%) than the ICAS (–) group (100.0%; p < 0.001). All the remaining patients in
the ICAS (+) group required specific rescue treatments appropriate for ICAS, including
balloon angioplasty, stenting, or intra-arterial glycoprotein IIb/IIIa inhibitor infusion to
obtain a successful recanalization. Procedural time was not significantly longer in the
ICAS (+) group. The rates of favorable outcomes (37.5% vs. 41.5%; p = 0.740), death,
and symptomatic intracerebral hemorrhage were not significantly different between
the groups.
Conclusion: ICAS-LVO was common in patients who underwent EVT for acute
vertebrobasilar LVO. Although conventional modalities were often ineffective for
vertebrobasilar ICAS-LVO, a comparable recanalization rate could be obtained with
ICAS-specific modalities. Recanalization rate and procedural time were comparable, and
clinical outcomes did not differ between patients with or without ICAS-LVO.
Keywords: endovascular treatment, intracranial atherosclerosis, vertebrobasilar occlusion, occlusion type, clinical
outcome
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INTRODUCTION
Due to the significant improvement of recanalization rate in
modern endovascular treatment (EVT) of large vessel occlusion
(LVO), we are now focusing on types of intractable cases (1–4).
An LVO caused by in situ thrombo-occlusion from underlying
intracranial atherosclerosis (intracranial atherosclerosis-related
LVO, ICAS-LVO) is considered one of the intractable cases.
Subsequently, devising an optimal endovascular strategy for
management of ICAS-LVO is important. Then, for an optimal
endovascular strategy, reliable information is required such as
prediction, procedural details, and endovascular and clinical
outcomes of ICAS-LVO.
Because ICAS-LVO is more frequent in posterior circulation
(5–7), an endovascular strategy for ICAS-LVO might be more
important in procedures for vertebrobasilar LVO than LVO in
anterior circulation.Moreover, patients with vertebrobasilar LVO
have higher morbidity and mortality compared with LVO in
anterior circulation (8, 9). Although there are several nonspecific
factors affecting the prognosis of acute vertebrobasilar LVO (10),
they have not been actively utilized when selecting patients
eligible for EVT (11–13). In fact, all recent randomized controlled
trials were performed only with LVO in anterior circulation,
and substantial criteria were established to minimize futile
recanalization of LVO in anterior circulation. In contrast to
LVO in anterior circulation, greater focus has been on the
recanalization procedure in vertebrobasilar LVO rather than
patient selection factors. Therefore, efficient recanalization of
ICAS-LVO might be a more important issue especially in
vertebrobasilar LVO. In addition, EVT of the vertebrobasilar
ICAS-LVO should be understood in the context of patient
clinical outcomes.
Information regarding vertebrobasilar ICAS-LVO is lacking.
The procedural details and endovascular and clinical outcomes
of vertebrobasilar ICAS-LVO have been reported in only a few
studies (6, 7). Accordingly, we evaluated the procedural details
and clinical outcomes of vertebrobasilar ICAS-LVO patients
treated with EVT.
METHODS
We retrospectively reviewed consecutive acute stroke patients
who underwent EVT for intracranial LVO in posterior
circulation in a tertiary stroke center from September 2010
to June 2018. The intracranial LVO was restricted to occlusion
of a basilar artery or intracranial segment of a vertebral
artery (vertebrobasilar artery). The Institutional Review Board
approved this study and waived the requirement of informed
consent for this study due to its retrospective design. For
patients eligible for intravenous tissue-type plasminogen
activator (tPA) treatment, a full dose (0.9 mg/kg) of tPA was
administered. EVT was considered for patients with a computed
tomography angiography (CTA)-determined endovascularly
accessible LVO relevant to neurological symptoms, initial
National Institutes of Health Stroke Scale score ≥ 4, and stroke
onset within 12 h.
Endovascular Treatment
According to the predetermined protocol, a stent retriever
(Solitaire; Medtronic, Minneapolis, MN or Trevo; Stryker,
Kalamazoo, MI) was used as the first endovascular modality in
most procedures. A balloon-guiding catheter was not used in
endovascular procedures. All procedures were performed under
local anesthesia.
In patients with LVO who did not respond to several trials
of stent retriever or who showed significant stenosis on the
occlusion segment, rescue EVTs were considered. Endovascular
modalities for rescue were contact aspiration thrombectomy
with Penumbra Reperfusion Catheter (Penumbra, Alameda, CA)
or Sofia (Microvention, Tustin, CA), intra-arterial urokinase
infusion, balloon angioplasty, intracranial stenting, and/or intra-
arterial glycoprotein IIb/IIIa inhibitor (GPI) infusion. Decision
for optimal rescue endovascular modalities was based on the
operator’s best judgment. In most patients who underwent
intracranial stenting, intra-arterial GPI was administered to
resolve or prevent in-stent thrombosis. We performed the flat-
panel CT before GPI infusion in most cases of patients. Although
we did not have a specific criterion of unfavorable condition for
GPI infusion, large contrast enhancement was the most common
reason not to use GPI or to lessen the total dose of GPI. Typically,
5–10mg of abciximab (typically 1–2 mg/min) or 0.5–2.0mg
of tirofiban (0.05 mg/ml concentration with 0.1 mg/min) was
infused intra-arterially. To secure the stability of arterial patency
after balloon angioplasty, intracranial stenting, or intra-arterial
GPI infusion, serial delay angiograms were collected for at least
20min after recanalization. The procedure was finished only
when significant angiographic worsening was not observed in
arterial patency or perfusion status. Intravenous maintenance of
GPI after the EVT was also considered if necessary. Oral dual
antiplatelet medication was started from the day after the EVT
procedure if there was no significant intracranial hemorrhage or
other hemorrhagic complication.
Successful recanalization was defined as a modified
Thrombolysis Cerebral Ischemia grade 2b or 3, which should not
accompany reocclusion events on delay angiograms. Reocclusion
event was defined as a complete or incomplete occlusion event
after sufficient recanalization. To identify the reocclusion events,
follow-up angiography was performed for at least 20min after
recanalization in all patients.
Determination of ICAS-LVO
ICAS-LVO was determined based on occlusion type. All
occlusions were classified as either branching site or truncal
type primarily based on digital subtraction angiography (DSA)
findings (14). Briefly, if arterial bifurcation and all its distal
branches beyond the occlusion segment were saved, it was
considered a truncal-type occlusion. Based on the principal
theory, the truncal-type occlusion can be regarded as an ICAS-
LVO (Figures 1,2).
The occlusion type was assessed by 2 independent
neurointerventionalists. The kappa value for the inter-rater
reliability of DSA-determined occlusion type was 0.92.
Discrepant cases were decided by consensus among reviewers.
For cases whose occlusion type could not be determined based
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FIGURE 1 | A representative example of 67-year old male patient with branching-site occlusion. (A,B) Basilar artery (BA) occlusion was noted on preprocedural
computed tomography angiography (A, coronal view of maximal intensity projection image; arrow) and digital subtraction angiography (B, anteroposterior view). BA
bifurcation site was not clearly seen on preprocedural computed tomography angiography (dotted circle). (C) Post-deployment angiogram showed only unilateral
posterior cerebral artery was observed, which could be considered as a finding of branching-site occlusion (branch-missing sign). Distal marker of the stent retriever
was seen on the angiogram (arrow). (D) With 1 stent retriever thrombectomy, the BA was completely recanalized. (E) On follow-up magnetic resonance angiography
(time-of-flight image) performed 1 day after procedure, the recanalized BA was patent. (F) Only multiple tiny acute infarctions were noted in bilateral cerebellum and
occipital lobe on diffusion-weighted magnetic resonance images. The patient discharged without any neurologic deficits, whose modified Rankin Scale score was 0 at
3 months after stroke.
FIGURE 2 | A representative example of 80-year old female patient with truncal-type occlusion. (A) On preprocedural computed tomography angiography (coronal
view of maximal intensity projection image), occlusion of basilar artery (BA) was noted (arrow). On the computed tomography angiography, BA bifurcation was clearly
seen (arrowhead). (B) On digital subtraction angiography (anteroposterior view), BA occlusion was also noted. BA bifurcation (arrow) and bilateral posterior cerebral
arteries were seen by collateral flows through left anterior inferior cerebellar artery (arrowhead). (C) BA bifurcation and bilateral posterior cerebral arteries were definitely
verified by stent-through flow. (D) By 1 stent retriever thrombectomy, BA occlusion was recanalized, however, focal stenosis with angiographical haziness was noted
at the original occlusion site (arrow). (E) The recanalized BA was immediately reoccluded. Even with intra-arterial administration of tirofiban 0.5mg, BA was not
recanalized. (F) Intracranial stenting with Solitaire (Medtronic, Minneapolis, MN) was performed across the occlusion segment. Distal marker of Solitaire was observed
at distal BA (arrowhead). Despite intracranial stenting, arterial patency was not well maintained, which suggested an impending occlusion (arrow). (G) Balloon
angioplasty with Gateway (Stryker, Kalamazoo, MI) was performed. (H) BA was successfully recanalized with mild stenosis and did not show reocclusion event. (I) On
follow-up magnetic resonance angiography (time-of-flight image) performed 1 day after procedure, distal BA flow was well maintained. (arrow) (J) Acute infarction was
noted in most of right pons on diffusion-weighted magnetic resonance images. Her modified Rankin Scale score was 5 at 3 months after stroke.
on DSA, mostly due to poor image quality or invalid distal
confirmation, the occlusion type was determined using CTA
(15). Inter-rater reliability of the CTA-determined occlusion type
was excellent (kappa, 0.98).
Clinical Outcomes
Clinical outcomes included functional outcome, death, and
symptomatic intracerebral hemorrhage (SICH). Functional
outcome and death were assessed using the modified Rankin
Scale (mRS) score at 3 months after stroke onset. Favorable
outcome was defined as mRS score 0–2. The functional outcome
was primarily evaluated by stroke neurologists during the
patient’s routine clinic follow-up at 3 months ± 2 weeks. If
a patient could not come to the clinic, a stroke neurologist
or trained nurse interviewed the patient or their family via
telephone to determine the mRS score.
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ICH was evaluated on follow-up CT or magnetic resonance
(gradient echo) images obtained 24 ± 6 h after EVT. The ICH
was finally determined by consensus among stroke neurologists,
neurointerventionalists, and neuroradiologists during regular
stroke conferences. The determination of ICH was immediately
entered into the prospective registry. ICH was regarded as
symptomatic if National Institutes of Health Stroke Scale
score increased≥4.
Statistical Analysis
Based on the occlusion type determined, patients were assigned
to either the ICAS (+) group or the ICAS (–) group. Patients
with a truncal-type occlusion were assigned to the ICAS
(+) group. Demographics, common risk factors for stroke,
procedural details and outcomes, and clinical outcomes were
compared between ICAS (+) and ICAS (–) groups. Mann-
Whitney U test, χ2 test, and Fisher exact test were used
for comparison. Also, multivariable logistic regression analysis
was also performed to independent factors for favorable
outcome. For this analysis, age, variables with P-value < 0.1,
time profiles including onset-to-puncture and puncture-to-
recanalization time, and ICAS-LVO were adjusted. A P-value <
0.05 was considered statistically significant with a 95% confidence
interval (CI). Statistical analyses were performed using
software (version 3.4.2; r-project.org).
RESULTS
Among 604 patients who underwent EVT for an intracranial
LVO, 77 (mean age, 73.2 ± 12.8 years; male, 53.2%) were
finally included (Figure 3). Patients with distal artery occlusion
(n = 16) and etiology of arterial dissection (n = 2) were also
excluded. In the study population, 69 patients (89.6%) had
a basilar artery occlusion and 8 (10.4%) had an intracranial
vertebral artery occlusion. Occlusion type was determined based
on DSA in 67 patients (87.0%) and CTA in 10 patients (13.0%).
Among the included patients, 24 (31.2%) had an ICAS-LVO.
Atrial fibrillation was less frequent in the ICAS (+) group,
whereas intravenous tPA was more frequent in the ICAS (+)
group (Table 1). Stroke severity was not significantly different
between groups—median initial NIHSS score in the ICAS (+)
group was 14.5 and 12.0 in the ICAS (–) group (P = 0.624;
Supplemental Figure 1).
Procedural Details and Outcomes
Successful recanalization was achieved in 64 patients (83.1%).
Successful recanalization rate in the ICAS (+) group was similar
to that in the ICAS (–) group (79.2% vs. 84.9%; P = 0.529;
Table 2). All patients in the ICAS (–) group obtained a successful
recanalization with conventional endovascular modalities,
of which most (93.3%) were mechanical thrombectomy
devices. Conversely, only 36.8% of patients in the ICAS (+)
group achieved a successful recanalization with conventional
endovascular modalities (P < 0.001). The remaining patients
in the ICAS (+) group (63.2%; n = 12) eventually required
ICAS-specific modalities to achieve a successful recanalization,
including intra-arterial GPI infusion, balloon angioplasty, and
FIGURE 3 | Flow chart of patient selection. ICAS indicates intracranial
atherosclerosis.
intracranial stenting. Among the 12 patients treated with ICAS-
specific modalities, 8 obtained a successful recanalization only
with GPI infusion (66.7%), and 3 (25.0%) eventually required
rescue stenting. For intracranial stenting, Solitaire was used in
all cases. In patients in the ICAS (+) group treated with GPI
(n = 11), abciximab was infused in 6 (54.5%; mean dose, 9.2 ±
3.4mg) and tirofiban in 5 patients (45.5%; 0.7± 0.2 mg).
Reocclusion events after initial recanalization using
conventional endovascular modalities were observed more
frequently in the ICAS (+) group than in the ICAS (–) group
(62.5% vs. 5.7%; P < 0.001; Table 2). In 15 patients with
reocclusion events in the ICAS (+) group, GPI was used in
13 (86.7%). Reocclusion events were resolved only with GPI
infusion in 8 patients (61.5%; 8 of 13). For patients in whom GPI
infusion was unsuccessful, additional consecutive intracranial
stenting with balloon angioplasty provided more recanalization
in 3 patients (23.1%; 3 of 13). Altogether, 84.6% (11 of 13) of
patients with reocclusion events were successfully recanalized
with GPI infusion and/or consecutive intracranial stenting with
balloon angioplasty.
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TABLE 1 | Comparison of variables between patients with and without
vertebrobasilar intracranial atherosclerosis-related acute large vessel occlusion
(ICAS-LVO).
Total
patients
(n = 77)
ICAS (+)
(n = 24)
ICAS (–)
(n = 53)
P-value Odds ratio*
(95% CI)
Age, years 73.2 (±12.8) 72.7 (±13.8) 73.5 (±12.5) 0.800 0.99
(0.96–1.03)
Sex, male 41 (53.2) 14 (58.3) 27 (50.9) 0.547 1.34
(0.51–3.57)
Hypertension 62 (80.5) 21 (87.5) 41 (77.4) 0.366 2.05
(0.52–8.06)
Diabetes 30 (39.0) 6 (25.0) 24 (45.3) 0.091 0.40
(0.14–1.17)
Dyslipidemia 19 (24.7) 6 (25.0) 13 (24.5) 0.965 1.03
(0.34–3.13)
Smoking 10 (13.0) 7 (29.2) 3 (5.7) 0.008 6.86
(1.59–29.6)
Coronary
artery disease
24 (31.2) 5 (20.8) 19 (35.8) 0.188 0.47
(0.15–1.46)
Atrial
fibrillation
36 (46.8) 7 (29.2) 29 (54.7) 0.037 0.34
(0.12–0.96)
Initial NIHSS
score
13.0
[7.0; 24.0]
14.5
[9.0; 21.5]
12.0
[7.0; 25.0]
0.624 1.00
(0.95–1.05)
Basilar artery
occlusion
69 (89.6) 16 (66.7) 53 (100.0) <0.001 N/A
Use of IV tPA 18 (23.4) 10 (41.7) 8 (15.1) 0.011 4.02
(1.33–12.1)
Onset-to-
puncture,
min
262.0
[146.0; 435.0]
207.0
[158.0; 307.8]
285.0
[140.0; 475.0]
0.253 0.94
(0.87–1.02)†
CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; IV tPA,
intravenous tissue plasminogen activator; N/A, not applicable.
Values in parentheses represent the standard deviation, number of patients (%), or
median; brackets represent first and third quartiles.
*Odds ratio for ICAS (+)
†
Odds ratio per 30min of time.
Median puncture-to-recanalization time was 46.5min
(interquartile range, 27.8–93.2; range, 9.0–273.0;
Supplemental Figure 2) and median onset-to-recanalization
time was 351.0min (interquartile range, 207.5–497.2;
range, 99.0–1020.0; Supplemental Figure 3). Puncture-
to-recanalization time was not significantly different
between the ICAS (+) and the ICAS (–) groups (52.0 vs.
45.0min; P = 0.837). Onset-to-recanalization time was not
significantly different between the groups, either (325.0 vs.
383.0min; P = 0.791).
Clinical Outcomes
Favorable outcome (37.5% vs. 41.5%; P = 0.740) and death
(16.7% vs. 22.6%; P = 0.763) were not significantly different
between the ICAS (+) and ICAS (–) groups (Table 2, Figure 4).
SICH developed in 4 patients (5.2%) in the study population.
SICH was higher in the ICAS (+) group than the ICAS (–)
group; however, the difference was not statistically significant
(12.5% vs. 1.9%; P = 0.087). SICH developed in 12.5% of
patients who underwent intra-arterial GPI infusion, which
TABLE 2 | Procedural and clinical outcomes of patients with and without
vertebrobasilar intracranial atherosclerosis-related acute large vessel occlusion
(ICAS-LVO).
Total
patients
(n = 77)
ICAS (+)
(n = 24)
ICAS (–)
(n = 53)
P-
value
Odds ratio*
(95% CI)
ENDOVASCULAR OUTCOMES
Successful
recanalization
64 (83.1) 19 (79.2) 45 (84.9) 0.529 0.68
(0.20–2.33)
Conventional
modalities
52 (81.2) 7 (36.8) 45 (100.0) <0.001 N/A
Stent
retriever
38 (59.4) 5 (26.2) 33 (73.3)
Contact
aspiration
thrombectomy
10 (15.6) 1 (5.3) 9 (20.0)
Urokinase 4 (6.2) 1 (5.3) 3 (6.7)
ICAS-specific
modalities
12 (18.8) 12 (63.2) 0 (0.0)
GPI 8 (12.5) 8 (42.1) 0 (0.0)
PTA 1 (1.6) 1 (5.3) 0 (0.0)
Stenting + PTA
+ GPI
3 (4.7) 3 (15.8) 0 (0.0)
Procedural Events
Reocclusion during
the procedure
18 (23.4) 15 (62.5) 3 (5.7) <0.001 27.8
(6.66–115.9)
Puncture-to-
recanalization,
min
46.5
[27.8; 93.2]
52.0
[25.5;
117.5]
45.0
[28.0; 77.0]
0.837 1.07
(0.80–1.44)†
Onset-to-
recanalization,
min
351.0
[207.5;
497.2]
325.0
[243.0;
437.5]
383.0
[201.0;
529.0]
0.791 0.97
(0.90–1.06)†
CLINICAL OUTCOMES
Favorable outcome 31 (40.3) 9 (37.5) 22 (41.5) 0.740 0.85
(0.32–2.28)
Death 16 (20.8) 4 (16.7) 12 (22.6) 0.763 0.68
(0.20–2.39)
Symptomatic ICH 4 (5.2) 3 (12.5) 1 (1.9) 0.087 7.43
(0.73–75.5)
CI, confidence interval; GPI, glycoprotein IIb/IIIa inhibitor; PTA, percutaneous transluminal
angioplasty; ICH, intracerebral hemorrhage; N/A, not applicable.
Values in parentheses represent the number of patients (%) or median; brackets represent
first and third quartiles.
*Odds ratio for ICAS (+).
†
Odds ratio per 30min of time.
was not significantly higher than in patients who did not
receive intra-arterial GPI infusion (3.3%; P = 0.189). In
addition, use of intravenous tPA was not associated with
development of SICH (P = 0.999). For patients with basilar
artery occlusion (n = 69), clinical outcomes were not
significantly different between the ICAS (+) and ICAS (–) groups
(Supplemental Table).
In multivariable analysis, initial NIHSS score (odds ratio 0.82
with 95% confidence interval 0.74–0.91; P < 0.001; Table 3)
and puncture-to-recanalization time (odds ratio 0.81 per 10min
with 0.65–0.99; P = 0.046) were independent factors for
favorable outcome.
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FIGURE 4 | Distribution of modified Rankin Scale score at 3 months after treatment in patients with intracranial atherosclerosis-related large vessel occlusion (ICAS
[+]) and without (ICAS [–]).
DISCUSSION
In this study, ICAS-LVO comprised approximately 31% of all
vertebrobasilar LVOs eligible for EVT. Patients with ICAS-LVO
required specific rescue treatments appropriate for underlying
ICAS, which resulted in a successful recanalization rate
similar to that of patients without ICAS-LVO, and clinical
outcomes in patients with or without ICAS-LVO were not
significantly different.
ICAS-LVO is more frequent in patients with acute
vertebrobasilar occlusion eligible for EVT (6, 7). Kim et al.
reported that approximately 37% of ICAS-LVO in acute
vertebrobasilar artery occlusion has been observed in the
Korean population (6). The reported frequency of ICAS-LVO
did not differ from our study. Lee et al. also reported the
frequency of ICAS-LVO in acute basilar artery occlusion as
approximately 24%, similar to our study (23.2%; 16 of 69
basilar artery occlusions) (7). Because most ICAS-LVO studies
included LVOs in both anterior and posterior circulation,
comparing frequencies of ICAS-LVO between anterior and
posterior circulation is difficult (5, 16–18). The frequency of
ICAS-LVO in both circulations was approximately 8–23%,
far less than posterior circulation studies (6, 7). In addition,
posterior circulation involvement was an independent factor
associated with ICAS-LVO (5). The reason ICAS-LVO is more
prevalent in posterior circulation is unclear. However, an
optimal endovascular strategy for ICAS-LVO might be more
important in posterior than anterior circulation cases due to
higher frequency.
Clinical outcomes of patients with vertebrobasilar ICAS-
LVO who underwent EVT were not consistent in previous
studies. Lee et al. showed that patients with vertebrobasilar
ICAS-LVO had comparable clinical outcomes to those without
vertebrobasilar ICAS-LVO (7). Conversely, in another study,
patients with vertebrobasilar ICAS-LVO had a less favorable
outcome despite similar recanalization rates (6). Furthermore,
vertebrobasilar ICAS-LVO was an independent factor for
poor prognosis. One potential reason for the difference of
clinical outcome was procedural time. Based on those studies,
longer procedural time was associated with poor clinical
outcomes (7). In this study, time profiles including onset-
to-recanalization time and puncture-to-recanalization time
were not significantly longer in patients with vertebrobasilar
ICAS-LVO. In addition, clinical outcomes were also comparable
to those of patients without vertebrobasilar ICAS-LVO.
However, even in this study, puncture-to-recanalization time
was an independent factor for favorable outcome. Considering
the findings from previous and current studies, procedural
time could be an important factor that influences clinical
outcome in acute vertebrobasilar ICAS-LVO. Conversely,
recanalization success might be an important factor affecting
clinical outcomes of patients with ICAS-LVO of anterior
circulation because their clinical outcomes were proportional to
successful recanalization rate (16, 18–20).
Occlusion location might affect the stroke severity in LVO of
posterior circulation. In BA occlusion, patients with proximal
or middle clot had higher mortality than distal (21). Clinical
outcome was not favorable in proximal or middle clot, either.
Another study also showed a higher mortality in BA occlusion
with atherothrombosis, which were represented as a proximal
and middle BA occlusion (22). One possible explanation for
the more severe stroke severity in the ICAS-LVO group is the
involvement of pons perforator. In our study, an initial NIHSS
score was higher in the ICAS-LVO group. This might be come
from that branching-site occlusion absolutely involves distal BA
based on its original theory, while the truncal-type occlusion
might be possible at all segments of BA including its proximal
and middle part.
Procedural details to treat vertebrobasilar ICAS-LVO
are not well known. The feasibility of intracranial stenting,
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TABLE 3 | Univariable and multivariable analyses of variables affecting favorable
outcome.
Univariable analysis Multivariable
analysis
Favorable
outcome
(n = 31)
Unfavorable
outcome
(n = 46)
P-value Odds ratio
(95% CI)
P-value
Age, years 70.9 (±15.3) 74.8 (±10.8) 0.216 0.97
(0.92–1.04)
0.397
Sex, male 18 (58.1) 23 (50.0) 0.487
Hypertension 24 (77.4) 38 (82.6) 0.573
Diabetes 10 (32.3) 20 (43.5) 0.322
Dyslipidemia 6 (19.4) 13 (28.3) 0.374
Smoking 5 (16.1) 5 (10.9) 0.512
Coronary artery
disease
9 (29.0) 15 (32.6) 0.740
Atrial fibrillation 17 (54.8) 19 (41.3) 0.243
Initial NIHSS
score
7.0
[5.5; 11.5]
22.0
[12.2; 28.0]
<0.001 0.82
(0.74–0.91)
<0.001
Basilar artery
occlusion
29 (93.5) 40 (87.0) 0.463
Use of IV tPA 8 (25.8) 10 (21.7) 0.679
Onset-to-
puncture,
min
210.0
[123.0; 415.5]
265.5
[169.2; 440.2]
0.347 0.96
(0.86–1.06)*
0.414
Puncture-to-
recanalization,
min
35.0 56.0 0.001 0.81 0.046
[19.0; 58.0] [38.0; 130.5] (0.65–0.99)†
Onset-to-
recanalization,
min
264.0
[182.0; 443.0]
390.0
[294.0; 497.5]
0.180
Successful
recanalization
29 (93.5) 35 (76.1) 0.063
Reocclusion
during the
procedure
4 (12.9) 14 (30.4) 0.075 0.43
(0.04–5.07)
0.504
Use of GPI
during
procedure
5 (16.1) 11 (23.9) 0.409
Symptomatic
ICH
0 (0.0) 4 (8.7) 0.143
ICAS-related
large vessel
occlusion
9 (29.0) 15 (32.6) 0.740 1.10
(0.15–8.21)
0.924
CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; IV tPA,
intravenous tissue plasminogen activator; GPI, glycoprotein IIb/IIIa inhibitor; ICH,
intracerebral hemorrhage; ICAS, intracranial atherosclerosis.
Values in parentheses represent the standard deviation, number of patients (%), or
median; brackets represent first and third quartiles.
*Odds ratio per 30min of time.
†
Odds ratio per 10min of time.
balloon angioplasty, and intra-arterial GPI infusion, termed
ICAS-specific endovascular modalities in vertebrobasilar
ICAS-LVO, have been reported only in a few case series
(23, 24). Kim et al. only reported the use of ICAS-specific
modalities based on the presence of vertebrobasilar ICAS-LVO
(6). More ICAS-specific modalities were used in patients with
vertebrobasilar ICAS-LVO for rescue treatment. However,
the study did not offer detailed information regarding the
success rate of modern conventional modalities (e.g., stent
retriever or contact aspiration thrombectomy) or effectiveness
of each ICAS-specific modality in vertebrobasilar ICAS-LVO.
Procedural details of the current study were similar to those
of other studies on ICAS-LVO (18, 19, 23–26). To obtain a
successful recanalization, ICAS-LVO required significantly more
rescue treatments, which were all ICAS-specific modalities.
Apparently, ICAS-specific modalities were feasible and necessary
in most patients with vertebrobasilar ICAS-LVO. Interestingly,
among them, intra-arterial GPI infusion could be considered
as the first ICAS-specific modality. In this study, 66.7% of
patients who were treated by ICAS-specific modalities could
get a successful recanalization by intra-arterial GPI alone. In
anterior circulation ICAS-LVOs, intra-arterial GPI was effective
in about 40% of patients without the use of other ICAS-specific
modalities (20). According to the response to the first intra-
arterial GPI infusion, one might consider intracranial stenting or
balloon angioplasty.
In summary, the expected successful recanalization rate
in vertebrobasilar ICAS-LVO using modern conventional
modalities is not high, possibly less than 40%. In addition, ICAS-
specific endovascular modalities were quite feasible and effective.
Furthermore, shorter procedural time appears more important
in vertebrobasilar ICAS-LVO for better clinical outcome.
Rapid and active introduction of ICAS-specific modalities
should be considered as an optimal endovascular strategy in
vertebrobasilar ICAS-LVO.
SICH was not statistically different between patients with or
without ICAS-LVO; however, frequency of SICH in the ICAS
(+) group was higher than in the ICAS (–) group. Most likely,
the number of SICH cases was too small to reach statistical
significance in this study. Although the number of cases was too
small, none were associated with development of SICH among
variables used in this study, including use of intra-arterial GPI or
intravenous tPA. Further studies are necessary to verify this issue.
This study had several strengths and limitations. First,
this study was retrospective; thus, types and specific timing
of introduction of rescue endovascular modalities were not
protocolized. Although treatment protocol was fundamentally
predetermined, many stages during the endovascular procedures
were dependent on operator discretion. However, because a
reliable method to identify and treatment protocol to manage
ICAS-LVO do not exist, the results from this retrospective
study might help in the understanding of procedural details for
managing vertebrobasilar ICAS-LVO and devising an optimal
treatment protocol.
Second, occlusion type was used to identify ICAS-LVO. This
is the first study of vertebrobasilar ICAS-LVO that used occlusion
type for its identification. Occlusion type is considered a reliable
angiographical surrogate marker for ICAS-LVO during or before
an endovascular procedure (14, 15). Occlusion type could be
determined even in cases with persistent occlusion and had
excellent inter-rater reliability. More importantly, endovascular
strategy, which is devised from endovascular and clinical results
based on the occlusion type, might also be practical for daily
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EVT procedure. In our center, we actively use occlusion type in
identifying the ICAS-LVO in real practice. It might contribute
to the comparable procedural time for vertebrobasilar ICAS-
LVOs in this study, although it should be verified prospectively.
In spite of the clinical advantages, occlusion type might be
imperfect in identifying occlusion etiology in some situations.
For example, an occlusion by a large size of embolus might
be erroneously classified as a truncal-type occlusion. Although
occlusion types in this study were mostly determined by
DSA, CTA-determined occlusion type considerably depends on
collateral adequacy (15). Thus, it seems necessary to compare
the occlusion type with another angiographical definition of
ICAS-LVO for more reliability (1, 5).
Third, results from this study were derived from a single
stroke center in Asia, where ICAS is more prevalent. Thus,
generalizability might be limited to a specific population.
However, management of ICAS-LVO is challenging in modern
EVT, and its importance has been increasing in intractable cases
irrespective of ethnicity. Furthermore, in situations where only
minimal information regarding procedural and clinical outcomes
is available, the current study provides important baseline data
for vertebrobasilar ICAS-LVO.
CONCLUSIONS
ICAS-LVO was common in patients who underwent EVT
for acute vertebrobasilar LVO. Patients with a vertebrobasilar
ICAS-LVO achieved a comparably successful recanalization rate
with similar procedural time; however, those patients required
more rescue endovascular modalities specific to ICAS-LVO for
successful recanalization. The clinical outcomes were comparable
in patients with or without vertebrobasilar ICAS-LVO.
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